Monoclonal Antibodies for Alzheimer's Resources

In This Section

The American Academy of Neurology works to provide resources to help its members understand the current treatments available for mild cognitive impairment and Alzheimer's disease and how members can discuss with patients. 

Drug Name/ Brand Name

 

Manufacturer FDA Status Infusion Frequency  Allowed Anticoagulation or Antiplatelet in Trial

Aducanumab (Aduhelm)

 

Aducanumab update

Biogen

Approved 2021

Under the accelerated approval

Once every 4 weeks Did not allow patients anticoagulation or antiplatelet therapy

Lecanemab

(Leqembi)

Eisai Granted traditional approval on July 6, 2023 Bi-weekly Allowed patients with anticoagulation or antiplatelet therapy

Donanemab

(Kisunla)

Eli Lilly

Granted traditional approval on July 2, 2024

Once every 4 weeks  

Emerging Issues in Neurology

Emerging Issues in Neurology articles are designed to provide timely guidance to neurologists and other clinicians, derived from expert consensus about new or emerging issues, that have immediate implications for patient care but for which a formal evidence base is still evolving.

To help neurologists discuss these therapies with patients and caregivers, the AAN has developed this Emerging Issues in Neurology article:

Top Resources

Frequently Asked Questions

Recent News